Menu

In the News

April 12, 2021 • Press Releases

Inland Northwest Research Screens First Patient Worldwide for Study of Investigational Parkinson’s Disease Drug

GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]

April 9, 2021 • Press Releases

Statement to the FDA on Support for Aducanumab for Treatment of Early Stage AD

GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]

April 8, 2021 • In the News

USF Awarded Five-Year, $44.4 Million NIH Grant to Test Whether Computerized Brain Training Reduces Dementia Risk

GAP-Net site USF Health has received a grant from the NIH to study a computerized brain training exercise, and if it can reduce the disk of Alzheimer’s disease and other dementias. The National Institutes of Health (NIH) has awarded the University of South Florida (USF) total expected funds of $44.4 million over the next five […]

March 29, 2021 • In the News

KU Alzheimer’s Disease Center Receives Over $1 Million for Research

GAP-Net Site KU ADC has received over $1.3 million to research how exercise supports the brain as humans age. TOPEKA, Kan. (WIBW) – The University of Kansas Alzheimer’s Disease Center has received over $1 million to research how exercise could prevent Alzheimer’s. Senator Roger Marshall (R-Kan.) says the University of Kansas Alzheimer’s Disease Center has […]

March 24, 2021 • In the News

KU Alzheimer’s Disease Center Using $4.3 Million NIH Grant to Power its Research and Dementia Care Efforts

GAP-Net site Kansas University ADC was granted $4.3 million from the NIH to elevate dementia care in Kansas communities. Dementia researchers are convinced the path to beating back the life-robbing disease goes directly through clinical trials fueled by research volunteers willing to join the battle. That’s why the experts at the University of Kansas Alzheimer’s Disease […]

March 23, 2021 • In the News

Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit

GAP President John Dwyer speaks about GAP’s participation in the original Trailblazer trial, and our goals for TRAILBLAZER-ALZ 2. It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite some positive signals from […]

March 19, 2021 • In the News

Can Changes in Driving Habits Predict Cognitive Decline in Older Adults?

GAP-Net site Knight ADRC at Washington University in St. Louis received two grants to determine whether driving changes can identify people with mild and very mild cognitive impairment, and maybe even identify people in the earliest stage of Alzheimer’s disease. Every day in the U.S. in 2018, motor vehicle crashes killed more than 20 people […]

March 15, 2021 • Press Releases

Lilly’s TRAILBLAZER-ALZ 2 Trial is Partnering with the Global Alzheimer’s Platform Foundation® to Shatter the Slow Completion Timeframes of Alzheimer’s Clinical Trials

TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]

March 10, 2021 • Featured

U.S. Trials for Alzheimer’s “Seaweed Drug” Oligomannate Recruiting Participants

GAP-Net Site, The Cognitive and Research Center of New Jersey, talks about their participation in the GREEN MEMORY trial. The Alzheimer’s Drug, Oligomannate, approved in China and derived from seaweed, is now being studied in the U.S. in a Phase 3, multi-center clinical trial that is actively recruiting participants.  Oligomannate, a drug made from seaweed […]

March 1, 2021 • In the News

This Alzheimer’s Drug Made From Seaweed got Approved in China. Now it’s Being Tested in N.J.

GAP President John Dwyer spoke about the Green Valley clinical trial’s success in China, which is now being tested in North America. A new drug extracted from seaweed and inspired by traditional Chinese medicine has come to the United States, where researchers hope it will provide the breakthrough in Alzheimer’s treatment that has eluded us […]